IPP Bureau
Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %
By IPP Bureau - October 19, 2021
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
.jpg "Luke Coutinho launches e-commerce venture YouCareLifestyle")
Luke Coutinho launches e-commerce venture YouCareLifestyle
By IPP Bureau - October 19, 2021
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia
By IPP Bureau - October 19, 2021
Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region
WHO to take call on Covaxin's EUL on October 26th
By IPP Bureau - October 18, 2021
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
By IPP Bureau - October 18, 2021
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
By IPP Bureau - October 18, 2021
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
U.S. FDA advisory committee recommends J&J booster dose
By IPP Bureau - October 18, 2021
U.S. FDA to decide whether to authorize a booster dose in the coming days
Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
By IPP Bureau - October 18, 2021
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Resilience and Harvard announce five-year R&D alliance
By IPP Bureau - October 18, 2021
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
GPT Healthcare to go public to fund expansion
By IPP Bureau - October 18, 2021
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
Granules gets ANDA approval for Dofetilide capsules
By IPP Bureau - October 18, 2021
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Govt. removes export curbs on Covid-19 kits
By IPP Bureau - October 16, 2021
The export policy of all diagnostic kits and reagents (including instruments /apparatus) ... is being made free with immediate effect," the directorate general of foreign trade (DGFT) said in a notification
Metropolis Healthcare board approves acquisition of Hitech for Rs 636 crore
By IPP Bureau - October 16, 2021
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Dr Reddy’s Lab launches carmustine in the US market
By IPP Bureau - October 16, 2021
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
Lancet Respiratory Medicine publishes Phase 2 data of Medigen Covid-19 vaccine
By IPP Bureau - October 16, 2021
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
